A Quantitative Benefit–Risk Analysis of ChAdOx1 nCoV-19 Vaccine among People under 60 in Italy

The Oxford-AstraZeneca ChAdOx1 nCoV-19 is a vaccine against the COVID-19 infection that was granted a conditional marketing authorization by the European Commission in January 2021. However, following a report from the Pharmacovigilance Risk Assessment Committee (PRAC) of European Medicines Agency,...

Descripción completa

Detalles Bibliográficos
Autores principales: Palladino, Raffaele, Ceriotti, Daniele, De Ambrosi, Damiano, De Vito, Marta, Farsoni, Marco, Seminara, Giuseppina, Barone-Adesi, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229711/
https://www.ncbi.nlm.nih.gov/pubmed/34201330
http://dx.doi.org/10.3390/vaccines9060618

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229711/
https://www.ncbi.nlm.nih.gov/pubmed/34201330
http://dx.doi.org/10.3390/vaccines9060618

Ejemplares similares